146 related articles for article (PubMed ID: 33473176)
1. Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention.
Park JH; Kim JY; Choi JH; Park HS; Shin HY; Lee JM; Kim JW; Ko HJ; Chon S; Kim BK; Kim CS; Lim S
Int J Obes (Lond); 2021 Apr; 45(4):776-786. PubMed ID: 33473176
[TBL] [Abstract][Full Text] [Related]
2. Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada.
Wharton S; Liu A; Pakseresht A; Nørtoft E; Haase CL; Mancini J; Power GS; Vanderlelie S; Christensen RAG
Obesity (Silver Spring); 2019 Jun; 27(6):917-924. PubMed ID: 31062937
[TBL] [Abstract][Full Text] [Related]
3. Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland.
Haase CL; Serratore Achenbach MG; Lucrezi G; Jeswani N; Maurer S; Egermann U
Obes Facts; 2021; 14(5):568-576. PubMed ID: 34515194
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia.
Park JS; Kwon J; Choi HJ; Lee C
Medicine (Baltimore); 2021 Jan; 100(2):e23780. PubMed ID: 33466127
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real-world experience.
Alshehri A; AlFaris N; Al Qahtani AM; Shams M; Yahia M
Clin Obes; 2023 Aug; 13(4):e12594. PubMed ID: 37194338
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study.
Gorgojo-Martínez JJ; Basagoiti-Carreño B; Sanz-Velasco A; Serrano-Moreno C; Almodóvar-Ruiz F
Int J Clin Pract; 2019 Nov; 73(11):e13399. PubMed ID: 31397946
[TBL] [Abstract][Full Text] [Related]
7. [Impact on weight loss and body composition of a food education intervention associated with Liraglutide treatment to address obesity].
Dearos Sanchis M; Voltas Arribas B; Carrasco-Querol N; Sauras Colón E; Sánchez Juan C
Nutr Hosp; 2024 Jun; 41(3):585-593. PubMed ID: 38450509
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide Does Not Adversely Impact Fat-Free Mass Loss.
Grannell A; Martin WP; Dehestani B; Al-Najim W; Murphy JC; le Roux CW
Obesity (Silver Spring); 2021 Mar; 29(3):529-534. PubMed ID: 33528919
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting.
Leventhal-Perek S; Shani M; Schonmann Y
Fam Pract; 2023 Dec; 40(5-6):629-637. PubMed ID: 36477550
[TBL] [Abstract][Full Text] [Related]
10. Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study.
Capristo E; Panunzi S; De Gaetano A; Raffaelli M; Guidone C; Iaconelli A; L'Abbate L; Birkenfeld AL; Bellantone R; Bornstein SR; Mingrone G
Diabetes Metab; 2018 Jun; 44(3):235-242. PubMed ID: 29398254
[TBL] [Abstract][Full Text] [Related]
11. Weight loss and treatment patterns in a real-world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland (ADDRESS study).
Schultes B; Timper K; Cavadini G; Rüh J; Gerber PA
Diabetes Obes Metab; 2024 Mar; 26(3):1023-1032. PubMed ID: 38092710
[TBL] [Abstract][Full Text] [Related]
12. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
Lean ME; Carraro R; Finer N; Hartvig H; Lindegaard ML; Rössner S; Van Gaal L; Astrup A;
Int J Obes (Lond); 2014 May; 38(5):689-97. PubMed ID: 23942319
[TBL] [Abstract][Full Text] [Related]
13. Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.
Gomez-Peralta F; Lecube A; Fernández-Mariño A; Alonso Troncoso I; Morales C; Morales-Pérez FM; Guler I; Cadarso-Suárez C
Diabet Med; 2018 Nov; 35(11):1605-1612. PubMed ID: 29943854
[TBL] [Abstract][Full Text] [Related]
14. Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity.
Santini S; Vionnet N; Pasquier J; Gonzalez-Rodriguez E; Fraga M; Pitteloud N; Favre L
Obesity (Silver Spring); 2023 Jan; 31(1):74-82. PubMed ID: 36478514
[TBL] [Abstract][Full Text] [Related]
15. A single-center study on the biochemical effect and clinical effectiveness of liraglutide in Turkish patients.
Cetiner S
Eur Rev Med Pharmacol Sci; 2023 Sep; 27(18):8740-8753. PubMed ID: 37782186
[TBL] [Abstract][Full Text] [Related]
16. Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center.
Ferrari F; Fierabracci P; Salvetti G; Jaccheri R; Vitti J; Scartabelli G; Meola A; Magno S; Ceccarini G; Santini F
J Endocrinol Invest; 2020 Dec; 43(12):1779-1785. PubMed ID: 32594453
[TBL] [Abstract][Full Text] [Related]
17. Single-Center Experience of Using Liraglutide in Adolescents With Obesity +/- Type 2 Diabetes.
Dauleh H; Pasha M; Gad H; Haris B; Petrovski G; Afyouni H; Khalifa A; Shehzad S; Amin R; Chirayath S; Mohamadsalih G; Mohammed S; Malik RA; Hussain K
Cureus; 2024 Apr; 16(4):e58720. PubMed ID: 38779269
[TBL] [Abstract][Full Text] [Related]
18. Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
Tronieri JS; Fabricatore AN; Wadden TA; Auerbach P; Endahl L; Sugimoto D; Rubino D
Obes Facts; 2020; 13(6):572-583. PubMed ID: 33197917
[TBL] [Abstract][Full Text] [Related]
19. Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.
Russo GT; Labate AM; Giandalia A; Romeo EL; Villari P; Alibrandi A; Perdichizzi G; Cucinotta D
J Endocrinol Invest; 2015 Jan; 38(1):81-9. PubMed ID: 25173876
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
Khoo J; Hsiang J; Taneja R; Law NM; Ang TL
Diabetes Obes Metab; 2017 Dec; 19(12):1814-1817. PubMed ID: 28503750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
